|
|
|
| Efficacy and safety of Rabeprazole combined with itopride in the treatment of functional dyspepsia#br# |
| HU Yunfu |
| Department of Pharmacy, Maanshan Shiqiye Hospital, Anhui Province, Maanshan 243000, China |
|
|
|
Abstract Objective To investigate the efficacy and safety of rabeprazole enteric-coated tablet combined with itopapride in the treatment of functional dyspepsia (FD). Methods A total of 108 FD patients in Maanshan Shiqiye Hospital, Anhui Province from April 2019 to March 2021 were selected as the research subjects, and according to random number table method, they were divided into control group and study group, with 54 cases in each group. The control group was treated with Itopride, and the research group was treated with Rabeprazole Sodium Enteric-Coated Tablets on the basis of the control group. Both groups were treated for two weeks. The treatment effect, symptom score before and after treatment (upper abdominal burning, upper abdominal pain, early satiety, fullness after meal), serum gastrin (GAS) and motilin (MTL) levels, and incidence of adverse reactions were compared between the two groups. Results The therapeutic effect of study group was better than control group (P ＜ 0.05); after treatment, the scores of upper abdominal burning sensation, upper abdominal pain, early satiety and postprandial fullness in the two groups were lower than those before treatment, and those in the study group were lower than those in the control group (P ＜ 0.05); the levels of GAS and MTL in the two group were higher than those before treatment, and the study group were higher than those in the control group (P ＜ 0.05); there was no statistical significance in the rate of adverse reactions between the two groups (P ＞ 0.05). Conclusion Taking rabeprazole sodium enteric coated tablets and Itopride in the treatment of FD can improve the treatment effect of the disease, which may be related to the effective regulation of the contents of serum gas and MTL, and the safety is guaranteed, which is worth popularizing.
|
|
|
|
|
|
[1] Alexander CF，Moayyedi P，Christopher JB，et al. Systematic review and network meta-analysis：efficacy of drugs for functional dyspepsia [J]. Aliment Pharmacol Ther，2021，53（1）：8-21.
[2] 蔡清红，马松炎.达立通颗粒联合伊托必利治疗功能性消化不良临床观察[J].中国药业，2019，28（22）：58-60.
[3] 李娜.辨证艾灸联合伊托必利治疗功能性消化不良的疗效研究[J].湖南中医药大学学报，2019，39（1）：60-63.
[4] 张洋洋.复方消化酶、奥美拉唑及伊托必利治疗功能性消化不良的疗效[J].实用中西医结合临床，2019，19（3）：19-20.
[5] 肖洪亮.雷贝拉唑三联疗法对功能性消化不良患儿伴幽门螺杆菌感染的临床疗效评价[J].抗感染药学，2018，15（11）：1956-1958.
[6] Hiroshi Y，Futagami S，Keiko K，et al. Camostat Mesilate，Pancrelipase，and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities [J]. Digestion，2019，99（4）：283-292.
[7] 中华医学会消化病学分会胃肠动力学组，中华医学会消化病学分会胃肠功能性疾病协作组.中国功能性消化不良专家共识意见（2015年，上海）[J].中华消化杂志，2016，36（4）：217-229.
[8] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，2017：161-163.
[9] 黎冉冉.匹维溴铵联合伊托必利对功能性消化不良患者胃肠动力的影响分析[J].药品评价，2019，16（16）：38-39.
[10] 黄更珍，张耀丹，唐小波，等.雷贝拉唑联合舒肝解郁胶囊及益生菌治疗功能性消化不良及对胃肠激素的影响[J].川北医学院学报，2020，35（5）：798-801.
[11] Kamiya T，Shikano M，Kubota E，et al. A multicenter randomized trial comparing rabeprazole and itopride in patients with functional dspepsia in Japan：the NAGOYA study [J]. J Clin Biochem Nutr，2017，60（2）：130-135.
[12] 谭军.盐酸伊托必利联合艾司唑仑治疗功能性消化不良的价值体会[J].中国处方药，2020，18（7）：107-108.
[13] 王跃涛.伊托必利联合四联疗法对幽门螺杆菌阳性功能性消化不良患者的临床效果[J].中国民康医学，2020， 32（11）：127-129.
[14] 苗江虎，江华.三联药物方案对功能性消化不良患者胃肠排空率、症状缓解率及不良反应的影响[J].临床和实验医学杂志，2018，17（3）：308-311.
[15] 张静瑜，吕丹丹，谢燕东.雷贝拉唑联合莫沙必利治疗功能性消化不良患者的疗效观察[J].实用临床医药杂志，2020，24（16）：43-46.
[16] 姚朝阳，翟金玲.氟哌噻吨美利曲辛片联合莫沙必利及雷贝拉唑治疗功能性消化不良患者的疗效观察[J].数理医药学杂志，2020，33（3）：424-425.
[17] Toshihisa T，Yoshiaki T，Shinpei K，et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor：Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor [J]. J Gastroenterol Hepatol，2018，33（3）：623-630.
[18] 毛虹.复方消化酶联合雷贝拉唑及多潘立酮治疗功能性消化不良效果探讨[J].世界复合医学，2019，5（12）：180-182.
[19] Abid S，Jafri W，Zaman MU，et al. Itopride for gastric volume，gastric emptying and drinking capacity in functional dyspepsia [J]. World J Gastrointest Pharmacol Ther，2017，8（1）：74-80.
[20] 张丽，秦丽静，王艳芳，等.伊托必利、奥美拉唑、氟哌噻吨美利曲辛三联治疗功能性消化不良的效果及安全性[J].中国实用医刊，2020，47（19）：98-100.
[21] 李瑜斐.盐酸伊托必利联合氟哌噻吨美利曲辛片治疗功能性消化不良的临床效果[J].中国民康医学，2020， 32（1）：13-15.
[22] Hitoshi H，Tsuguhiro K，Yuichi K，et al. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors：Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors：randomized，multicenter open label exploratory study [J]. J Gastroenterol，2019，54（11）：972-983.
[23] 张静瑜，吕丹丹，谢燕东.雷贝拉唑联合莫沙必利治疗功能性消化不良患者的疗效观察[J].实用临床医药杂志，2020，24（16）：43-46.
[24] 李稳，丁媛媛，刘晨晨，等.马来酸曲美布汀联合莫沙比利对功能性消化不良的治疗效果及对血清5-HT NO SP与胃肠激素的作用研究[J].河北医学，2020，26（5）：740-744. |
|
|
|
